RIBOCICLIB PLUS BINIMETINIB FOR PATIENTS WITH WITH NRAS-MUTATED MELANOMA
Patients with melanoma have some relevant mutations, the most frequent being the BRAF mutation (40-60% of patients); this biomarker is also fundamental due to the success of the therapeutic target associated with it. Other relevant mutations are found in the NRAS genes (15-25% of cases), KIT, TERT and in the case of uveal melanomas, GNAQ […]
RIBOCICLIB PLUS BINIMETINIB FOR PATIENTS WITH WITH NRAS-MUTATED MELANOMA Read More »
